Depression

(Rac)-E1R (Compound 2) is the racemate of E1R. (Rac)-E1R is a sigma-1 receptor positive allosteric modulator (Sig1R PAM) used for the research of cognition/memory disorders.

(2R,3R)-E1R (Compound 2b) is an enantiomer of E1R. (2R,3R)-E1R is a sigma-1 receptor positive allosteric modulator (Sig1R PAM) for the treatment of cognition/memory disorders.

(2S,3S)-E1R (Compound 2d) is an enantiomer of E1R. (2S,3S)-E1R is a sigma-1 receptor positive allosteric modulator (Sig1R PAM) for the treatment of cognition/memory disorders.

(2R,3S)-E1R (Compound 2c) is an enantiomer of E1R. (2R,3S)-E1R is a sigma-1 receptor positive allosteric modulator (Sig1R PAM) for the treatment of cognition/memory disorders.

Flunamine is a broad-spectrum monoamine transporter inhibitor that inhibits the uptake of dopamine (DA), 5-hydroxytryptamine (5-HT), and noradrenaline (NA) in rat brain synaptosomes. The IC₅₀ values of Flunamine for DA and 5-HT uptake in rat striatal synaptosomes are 0.26 μM and 0.17 μM, respectively, and the IC₅₀ values for 5-HT and NA uptake in hypothalamic synaptosomes are 0.24 μM and 0.092 μM, respectively. Flunamine acts through broad-spectrum inhibition of dopaminergic, serotonergic, and noradrenergic monoamine reuptake and is used in research related to depression and Parkinson's disease.

N-Desmethyl clomipramine-d₇ (Desmethylclomipramine-d₇; Norclomipramine-d₇) is the deuterated-labeled N-Desmethyl clomipramine (HY-12388). N-Desmethyl clomipramine is the orally active major active metabolite of the tricyclic antidepressant Clomipramine (HY-B0457A), possessing multiple activities including anti-inflammatory, antioxidant, antibacterial, and antiparasitic effects. N-Desmethyl clomipramine blocks autophagosome-lysosome fusion, leading to the accumulation of LC3-II, p62, ATG7, WIPI2, and ATG5-12, reactivates the p53/p21 pathway, induces apoptosis through C-PARP and C-CAS3, and inhibits the proliferation, migration, and invasion of renal cancer cells. N-Desmethyl clomipramine inhibits LdTOPIA, inducing R-loop accumulation in the nucleus of Leishmania, ultimately causing parasite death. N-Desmethyl clomipramine can be used for research on depression, metastatic renal cell carcinoma, and leishmaniasis.

N-Desmethyl clomipramine-d₆ (Desmethylclomipramine-d₆; Norclomipramine-d₆) is the deuterated-labeled N-Desmethyl clomipramine (HY-12388). N-Desmethyl clomipramine (Desmethylclomipramine; Norclomipramine) is the orally active major active metabolite of the tricyclic antidepressant Clomipramine (HY-B0457A), possessing multiple activities including anti-inflammatory, antioxidant, antibacterial, and antiparasitic effects. N-Desmethyl clomipramine blocks autophagosome-lysosome fusion, leading to the accumulation of LC3-II, p62, ATG7, WIPI2, and ATG5-12, reactivates the p53/p21 pathway, induces apoptosis through C-PARP and C-CAS3, and inhibits the proliferation, migration, and invasion of renal cancer cells. N-Desmethyl clomipramine inhibits LdTOPIA, inducing R-loop accumulation in the nucleus of Leishmania, ultimately causing parasite death. N-Desmethyl clomipramine can be used for research on depression, metastatic renal cell carcinoma, and leishmaniasis.

Norfluoxetine oxalate is the active metabolite of the antidepressant Fluoxetine (HY-B0102); it is also a TREK-2 K₂P potassium channel inhibitor. Norfluoxetine oxalate exhibits neuroimmunological activity, induces apoptosis in primary microglial cells, and inhibits the release of pro-inflammatory factors. Norfluoxetine oxalate inhibits high-threshold voltage-gated Ca²⁺ currents in neurons with an EC₅₀ of 20.4 μM. Norfluoxetine oxalate can be used in research related to depression, ischemic stroke, and epilepsy.

25CN-NBOH hydrochloride exhibits agonist activity at the 5-HT_2a receptor, shows 90- to 100-fold selectivity over the 5-HT₂c receptor, and possesses blood-brain barrier permeability. 25CN-NBOH hydrochloride acts as an interoceptive agent with partial agonist-like properties. 25CN-NBOH hydrochloride serves as a pharmacological tool for 5-HT_2A receptor research, and its tritiated form functions as a selective agonist radioligand. 25CN-NBOH hydrochloride can be used to investigate diseases characterized by cognitive rigidity, schizophrenia, obsessive-compulsive disorder, depression, pain, inflammation, migraine, and cluster headache.

MDL 72394 (FMMT) is an orally active, blood-brain barrier-penetrant amino acid-based prodrug compound. MDL 72394 is decarboxylated by aromatic L-amino acid decarboxylase to generate the active metabolite MDL 72392 (HY-182727), which is a covalent irreversible MAO inhibitor. MDL 72394 is transported into the brain and synaptosomes via the L-neutral amino acid transport system and the norepinephrine transporter. MDL 72394 selectively inhibits MAO in noradrenergic and dopaminergic neurons without inhibiting serotonergic neurons. MDL 72394 increases hypothalamic extracellular 5-HT, tissue 5-HT, and pineal melatonin biosynthesis, and decreases 5-HIAA. MDL 72394 can be used in research related to MAO-mediated diseases, such as depression.

Carbazochrome sodium sulfonate trihydrate (AC-17 trihydrate) is a capillary stabilizer with anti-hemorrhagic properties and can be used in hemostasis-related research.

RB 101 hydrochloride is a blood-brain barrier-crossing prodrug as well as aminopeptidase N and neutral endopeptidase-24.11 inhibitor. RB 101 hydrochloride blocks enkephalin breakdown, elevates extracellular enkephalin levels and activate δ-opioid receptor and dopamine D1 receptor. RB 101 hydrochloride can be used for the research of pain, depressive syndromes, and diabetic neuropathy.

Mesembrenol is an alkaloid inhibitor of serotonin transporters and PDE4. Mesembrenol also inhibits glutamatergic AMPA receptors and can be used in research on mild to moderate depression.

18-Methoxycoronaridine ((-)-18-Methoxycoronaridine) is an orally active and selective α3β4 nicotinic acetylcholine receptor (nAChR) antagonist. 18-Methoxycoronaridine is an inhibitor of serotonin transporter (SERT) and norepinephrine transporter (NET), with IC₅₀ values of 51.6 μM and 121 μM for SERT and NET, respectively. 18-Methoxycoronaridine inhibits the function of SERT and NET, promotes 5-HT3A receptor desensitization, blocks α3β4 nAChR, and modulates receptor signaling pathways associated with reinforcement. 18-Methoxycoronaridine also exhibits potent antiparasitic activity. 18-Methoxycoronaridine can be used in research related to depression, obesity, alcoholism, smoking addiction, and cutaneous leishmaniasis.

Clorgyline hydrochloride (Standard) (M&B 9302 hydrochloride (Standard)) is the analytical standard of Clorgyline hydrochloride (HY-14197A). This product is intended for research and analytical applications. Clorgyline hydrochloride (M&B 9302 hydrochloride) is a selective, irreversible monoamine oxidase A (MAO-A) inhibitor that can cross the blood-brain barrier and exhibits activity against the 5-HT Receptor at very high doses. Clorgyline hydrochloride regulates monoamine neurotransmitter levels, the release of dopamine and acetylcholine, the uptake and effects of Tyramine (HY-W007606), noradrenergic function, circadian locomotor activity rhythms, feeding behavior, and body weight. Clorgyline hydrochloride induces tumor-suppressive transcriptional programs, secretory differentiation, androgen signaling regulation, Bcl-2 expression, and radioprotective effects in non-malignant cells. Clorgyline hydrochloride is used in the research of high-grade prostate cancer, Huntington's disease, major affective disorder, radiation-induced normal tissue toxicity, and obesity.

Gentisein (Standard) (NSC 329491 (Standard); 1,3,7-Trihydroxyxanthone (Standard)) is the analytical standard of Gentisein (HY-118166). This product is intended for research and analytical applications. Gentisein (NSC 329491) is a metabolite of Mangiferin (HY-N0290) that inhibits the serotonin transporter (5-HT uptake system). Gentisein suppresses serotonin uptake and can be used in studies related to depression.

Tofenacin (TOF) is an orally active weak anticholinergic compound. Tofenacin can be used to study extrapyramidal symptoms and depressive side effects associated with the use of Fluphenazine decanoate (HY-B1904) .

Eclanamine is an orally effective non-tricyclic antidepressant and an adrenergic receptor modulator. Eclanamine blocks biogenic amine uptake and enhances α2-receptor sensitivity, and long-term administration induces downregulation and desensitization of cortical β-receptors. Eclanamine is used in the study of depression.

Tofacitinib hydrochloride (Tasocitinib hydrochloride) is an orally active, blood-brain barrier permeable selective inhibitor of JAK1/JAK3. Tofacitinib hydrochloride blocks the JAK-STAT/NF-κB signaling pathway, inhibits cytokine signal transduction, phosphorylation of STAT1/STAT5, and suppresses innate and adaptive immune responses. Tofacitinib hydrochloride can be used in research related to major depressive disorder, rheumatoid arthritis, pulmonary diseases, systemic lupus erythematosus, and immune-mediated liver injury.

AGN‑2979 (SC 48274; BTG 1501) is an orally active and selective tryptophan hydroxylase inhibitor with antidepressant-like and anxiolytic-like activities. AGN‑2979 inhibits stress-induced activation of tryptophan hydroxylase, thereby limiting the biosynthesis of 5-hydroxytryptamine in the brain. AGN-2979 possesses non-sedative anxiolytic and cognitive-enhancing properties. AGN-2979 is applicable to research related to depression and generalized anxiety disorder.